top of page


Keith Lerro, MD, PhD

Keith Lerro, MD, PhD


Keith Lerro, MD, PhD

Clinical Interests: Oncology, Hematology

Fellowship: Hematology/Oncology, Yale University
Internship/Residency: Montefiore/Albert Einstein
Medical School: Albert Einstein College of Medicine
Undergraduate: University of Tampa
Certification/Awards: Board Certified in Oncology

Dr. Keith Lerro is a Board Certified Oncologist and Hematologist dedicated to using the latest treatments available against all types of cancer, even the most complex. Dr. Lerro received his cancer training at Yale University, residency at Montefiore, Albert Einstein College of Medicine and received his MD from Albert Einstein College of Medicine.

Post-Graduate Training:

  • Yale University School of Medicine, Connecticut. Fellow in Oncology/Hematology, 7/00 - 6/03.

  • Montefiore Medical Center, Albert Einstein College of Medicine, New York. Intern and Resident, 7/97 - 6/00.

  • Columbia University Chemistry Department, New York. Postdoctoral Fellow, 5/91 - 8/93.


  • Albert Einstein College of Medicine, New York. M.D., 8/93 - 5/97.

  • State University of New York at Stony Brook, Ph.D., Molecular Pharmacology 8/84 - 5/91.

  • University of Tampa, Florida. B.Sc., 8/80 - 5/84.



  • Medical Director, Regional Medical Oncology Center, Wilson, NC.  08/12 – present.

  • Attending Physician, Southeastern Medical Oncology Center, Wilson NC. 07/03 - 08/12.

  • Attending Physician, Internal Medicine, West Haven Veteran’s Administration Hospital, Connecticut 1/01 - 3/03.

  • Medical Director, Community Home Care and Hospice, Wilson, NC. 2012 – present.

  • Medical Director, Wilson Medical Center Hospice, Wilson, NC. 2004 – 2011.


Clinical Trial Experience:

  • Sargon Consortium- 2016-present- Pharmaceutical Industry Trials

  • Southeastern Medical Oncology Center, Phase II – IV Trials including but not limited to NSABP, CALGB, ECOG as a Principle Investigator and Sub-Investigator for multiple partners, 2003 – 2012.

  • Duke Cancer Network- 2020-present.


Professional Offices:     

  • President, North Carolina Oncology Association, 2018 - 2020

  • Board of Trustees, Healthcare Foundation of Wilson, 2014 - 2018.

  • President of Medical Staff, Wilson Medical Center, 2013 - 2014.

  • Board of Trustees, Wilson Medical Center, 2013 - 2014.

  • Medical Executive Committee, Wilson Medical Center, 2009 - present. 

  • President, Wilson County Medical Society, 2006.

  • Various Officer Positions, Wilson County Medical Society, 1/04-12/07.


Board Certification: Board Certified, Medical Oncology (2003, 2013). Board Eligible, Hematology and Internal Medicine.


Professional Societies: American Society of Clinical Oncology. North Carolina Medical Society, North Carolina Oncology Association



  • NCI medical student fellowship (1994).

  • Sigma Xi.

  • Outstanding College Students of America.

  • NIH graduate student fellowship (1984 -1991).

  • Synaptic post-doctoral fellowship (1991 - 1993);



  1. Lilenbaum R, Wang X, Gu L, Kirshner J, Lerro K, Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clinical Oncology 2009; 27: 4487-4491.

  2. Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, and Cooper DL. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents. Bone Marrow Transplant 2003; 32: 1113-1117.

  3. Lerro KA and Lacy J. Case report: A patient with primary CNS lymphoma treated with temozolomide to complete response. J Neuro-onc 2002; 59: 165-168.

  4. Ozuah PO, Burton W, Lerro KA, Rosenstock J, and Mulvihill M. Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 1999; 116: 104-106.

  5. Lerro KA. Are antihistamines beneficial in treating the negative symptoms of schizophrenia? Einstein Quart J Biol Med 1996; 13: 98-101.

  6. Frishman WH, Weiser S, Lerro KA, Retter A, Fadal A, and Hussain J. Innovative drug targets for treating cardiovascular disease: adhesion molecules, cytokines, neuropeptide Y, and bradykinin, in “Cardiovascular Pharmacotherapeutics” (Frishman WH and Sonnenblick EH, eds) McGraw-Hill, New York 1996: 837-880.

  7. Rao S, Lerro KA, Horwitz SB, Ojima I, Duclos O, Dorman G, Simonot B, and Prestwich GD. A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. J Med Chem 1995; 38: 3891-94.

  8. Nakanishi K, Zhang H, Lerro KA, Takekuma S, Yamamoto T, Hung-Lien T, Sastry L, Baek KJ, Moquin-Pattey C, Boehm MF, Derguini F, and Gawinowicz MA. Photoaffinity labeling of rhodopsin and bacteriorhodopsin. Biophys Chem 1995; 56: 13-22.

  9. Zhang H, Lerro KA, Yamamoto J, Hung-Lien T, Sastry MA, and Nakanishi K. The location of the chromophore in rhodopsin: a photoaffinity study. J Am Chem Soc USA 1994; 116: 10165-73.

  10. Zhang H, Lerro KA, Takekuma S, Baek KJ, Moquin-Pattey C, Boehm M, Nakanishi K. Orientation of the retinal 9-methyl group in bacteriorhodopsin, as studied by photoaffinity labeling. J Am Chem Soc USA 1994; 116: 6823-6831.

  11. Nakanishi K, Choi SK, Hwang D, Lerro KA, Orlando M, Kalivretenos AG, Eldefrawi A, Eldefrawi M, and Usherwood PNR. Bioorganic studies of transmitter receptors with philanthotoxin analogs. Pure & Appl Chem 1994; 66: 671-78.

  12. Lerro KA, Orlando R, Zhang H, Usherwood PNR, and Nakanishi K. Separation of sticky peptides from membrane proteins by high-performance-liquid-chromatography in a normal-phase system. Anal Biochem 1993; 215: 38-44.

  13. Moquin-Pattey C, Lerro KA, Nakanishi K, Orlando R, and Kenney PTM. Sequencing membrane proteins by tandem mass-spectrometry. Org Mass Spectrom 1993; 28: 1395-1402.

  14.  Touhara K, Lerro KA, Bonning BC, Hammock BC and Prestwich GD. Ligand binding by a recombinant insect juvenile hormone binding protein. Biochemistry 1993; 32: 2068-75.

  15. Prestwich GD, Touhara K, Atkinson JK, Lerro KA, Latli B, Okot-Dotber M, and Ujvary I. Hot juvenile hormone: using radioligands and photoaffinity labels to decipher the molecular action of juvenile hormone, in “Insect Juvenile Hormone Research, Fundamental and Applied Approaches: Chemistry, Biochemistry, and Mode of Action” (Mauchamp B, Couillaud F, and Baehr JC, eds) INRA, Paris 1992: 248-256.

  16. Lerro KA and Prestwich GD. Cloning and sequencing of a cDNA for the hemolymph juvenile hormone binding protein of larval Manduca Sexta. J Biol Chem 1990; 265: 19800-06.

  17. Grant AJ, Lerro KA, and Wu CW. Cell-associated elastase activities of rat mammary tumor cells. Biochem Internatl 1990; 22: 1077-84.

  18. Mohamed MA, Lerro KA, and Prestwich GD. Polyacrylamide gel miniaturization improves protein visualization and autoradiographic detection. Anal Biochem 1989; 177: 287-90.

bottom of page